Sorafenib(LuciSora)

Another NameNexavar、多吉美、索拉非尼

Indications

Indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and progressive differentiated thyroid cancer that is refractory to radioactive iodine therapy.

Specs

200mg*120tabs/box

WhatsApp

Factory:Lucius Pharmaceuticals

Reg No.:10 L 1224/24

Inspection No.:2562-24

Dosage form:Tablet

Indate:24 months

Warm tips:Please purchase and use the medication under pharmacist guidance as the outer packaging is for reference only and the information is intended for professionals.

Introduction of Sorafenib

Sorafenib was initially approved in the United States in 2005, and the latest revised prescribing information is dated August 2023.

Medicine-related columns

Instructions of Sorafenib

Indicated Population

Indicated for adult patients with unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or radioactive iodine-refractory differentiated thyroid cancer.

Dosage and Administration

The recommended dosage is 400 mg twice daily, taken on an empty stomach.

Use in Specific Populations

Patients of reproductive potential should use effective contraception; no dose adjustment is required in elderly patients or those with mild to moderate hepatic or renal impairment.

Overdosage

Overdosage may present with diarrhea and skin reactions; discontinue the drug and provide supportive care.

Pharmacokinetics

After oral absorption, sorafenib is metabolized in the liver, with a half-life of approximately 25–48 hours.

Recommended Articles

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More